Recombinant human FGFR2 protein (Fc Chimera) (ab55759)
Key features and details
- Expression system: Insect cells
- Purity: > 90% SDS-PAGE
- Active: Yes
- Suitable for: SDS-PAGE
-
Product name
Recombinant human FGFR2 protein (Fc Chimera)
See all FGFR2 proteins and peptides -
Biological activity
Determined by its ability to inhibit human FGF acidic dependent proliferation on R1 cells. The ED50 for this effect is typically at 15.0-30.0 ng/ml.
-
Purity
> 90 % SDS-PAGE.
Purity: > 90%, by SDS-PAGE and visualised by silver stain. Endotoxin level: -
Expression system
Insect cells -
Accession
-
Protein length
Protein fragment -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
RPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVIS WTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFM VNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPA ANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESV VPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVG GDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTD KEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITA SPDYLEDPRRASIEGRGDPEEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK -
Amino acids
22 to 377 -
Additional sequence information
Fused with the Fc region of Human IgG1 at the C-terminus via a Xa cleavage site.
-
Preparation and Storage
- bacteria-expressed kinase
- BBDS
- BEK
Images
-
SDS-PAGE - Recombinant human FGFR2 protein (Fc Chimera) (ab55759)SDS-PAGE analysis of recombinant human soluble FGFR-2/Fc produced in insect cells. Sample was loaded in 10% SDS-polyacrylamide gel under reducing condition and stained with Coomassie blue.
-
Functional Studies - Recombinant human FGFR2 protein (Fc Chimera) (ab55759)Inhibition of the basic FGF-induced proliferation of HUVE cells by recombinant human sFGFR-2-Fc. HUVECs were stimulated with 10 ng/ml bFGF, the soluble receptor was added with a 50 - 200X excess.
